-
ONCONASE maker announces move toward completion of IIIB mesothelioma clinical trials Alfacell announced its third-quarter financial results with optimism about its chemotherapy drug Onconase, which is in the process of completing IIIB clinical trials for the treatment of inoperable mesothelioma, a rare form of cancer caused by asbestos exposure. In addition to progress […]